The pharmaceutical company's consolidated net profit tumbled 55.32% to Rs 102.98 crore on 3.08% slide in revenue from operations to Rs 1,380.90 in Q4 FY23 over Q4 FY22.

Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic Active Pharmaceutical Ingredients (APIs) and a major focus on anti-retroviral, oncology drugs, Cardiovascular, Gastro and Hepatitis C therapeutics. The company also develops and manufactures oral solid formulations, provide contract research and manufacturing services (CRAMS) to Global pharma companies.